MMS
MMS
Maximus, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.35B ▲ | $161.14M ▼ | $93.94M ▲ | 6.98% ▲ | $1.71 ▲ | $178.59M ▲ |
| Q4-2025 | $1.32B ▼ | $187M ▲ | $75.29M ▼ | 5.71% ▼ | $1.34 ▼ | $160.07M ▼ |
| Q3-2025 | $1.35B ▼ | $170.76M ▲ | $105.98M ▲ | 7.86% ▲ | $1.87 ▲ | $198.24M ▲ |
| Q2-2025 | $1.36B ▼ | $162.86M ▲ | $96.57M ▲ | 7.09% ▲ | $1.7 ▲ | $186.37M ▲ |
| Q1-2025 | $1.4B | $153.27M | $41.2M | 2.94% | $0.69 | $117.97M |
What's going well?
Profits and earnings per share jumped, even with only modest revenue growth. The company managed to cut operating expenses significantly, showing strong cost discipline.
What's concerning?
Gross margins are slipping as costs rise faster than sales. The business remains low-margin, so any further cost increases could quickly hurt profits.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $137.59M ▼ | $4.21B ▲ | $2.49B ▲ | $1.72B ▲ |
| Q4-2025 | $260.46M ▲ | $4.07B ▼ | $2.4B ▼ | $1.67B ▼ |
| Q3-2025 | $105.38M ▼ | $4.46B ▲ | $2.69B ▲ | $1.77B ▲ |
| Q2-2025 | $155.94M ▲ | $4.2B ▲ | $2.53B ▲ | $1.67B ▲ |
| Q1-2025 | $122.87M | $4.06B | $2.41B | $1.65B |
What's financially strong about this company?
The company has positive equity, a solid current ratio, and a long history of profits. Most debt is long-term, and there are no major hidden risks.
What are the financial risks or weaknesses?
Cash reserves are falling fast, and debt is rising. Over half of assets are goodwill and intangibles, which could be written down if business weakens.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $93.94M ▲ | $-244.4M ▼ | $6.63M ▲ | $156.9M ▲ | $-80.93M ▼ | $-250.66M ▼ |
| Q4-2025 | $75.29M ▼ | $649.37M ▲ | $-3.15M ▲ | $-490.67M ▼ | $116.97M ▲ | $641.85M ▲ |
| Q3-2025 | $105.98M ▲ | $-182.72M ▼ | $-15.49M ▲ | $146.12M ▲ | $-50.56M ▼ | $-198.21M ▼ |
| Q2-2025 | $96.57M ▲ | $42.71M ▲ | $-19.37M ▲ | $8.93M ▲ | $33.07M ▲ | $25.51M ▲ |
| Q1-2025 | $41.2M | $-80M | $-22.26M | $-8.26M | $-112.89M | $-102.99M |
What's strong about this company's cash flow?
The company was able to borrow $233 million and still return $57 million to shareholders. Net income is positive, and capital spending is low.
What are the cash flow concerns?
Operating cash flow and free cash flow swung deep into the red, mainly due to working capital issues. The company is now dependent on borrowing, and cash reserves are shrinking quickly.
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Clinical Services | $500.00M ▲ | $560.00M ▲ | $570.00M ▲ | $520.00M ▼ |
Technology Solutions | $90.00M ▲ | $80.00M ▼ | $0 ▼ | $70.00M ▲ |
Revenue by Geography
| Region | Q1-2022 | Q2-2022 | Q3-2022 | Q4-2022 |
|---|---|---|---|---|
AUSTRALIA | $50.00M ▲ | $50.00M ▲ | $40.00M ▼ | $30.00M ▼ |
Rest of World | $40.00M ▲ | $50.00M ▲ | $50.00M ▲ | $40.00M ▼ |
UNITED KINGDOM | $90.00M ▲ | $110.00M ▲ | $110.00M ▲ | $110.00M ▲ |
UNITED STATES | $970.00M ▲ | $970.00M ▲ | $920.00M ▼ | $1.00Bn ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Maximus, Inc.'s financial evolution and strategic trajectory over the past five years.
Core strengths include steady revenue growth, a sharp recovery in margins and earnings, strong and recurring operating cash flow, and a solid niche position in government services. Long-standing relationships with public agencies, combined with growing technology capabilities, create meaningful barriers to entry. Liquidity has improved, giving the company more flexibility to manage working capital, invest selectively, and support shareholder returns.
Risks center on sizable and somewhat variable debt levels, volatile free cash flow and capital spending, and rising overhead costs that could pressure margins if not controlled. The business is also exposed to contract concentration, competitive bidding, and shifts in government policy or funding, which can affect both revenue visibility and pricing. The lack of a formal R&D line makes it harder to track innovation investment, raising questions about how consistently it will be funded over time.
The overall picture points to a company that has emerged from a weaker period into stronger growth and profitability, with innovation‑driven offerings that resonate with government clients. If Maximus can maintain cost discipline, manage leverage prudently, and keep advancing its technology and analytics capabilities, it appears well positioned to pursue additional contract wins and incremental margin gains. However, its future path will remain closely tied to government spending trends, competitive dynamics in federal and state contracting, and management’s choices around debt, buybacks, and investment intensity.
About Maximus, Inc.
https://www.maximus.comMaximus, Inc. provides business process services (BPS) to government health and human services programs. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.35B ▲ | $161.14M ▼ | $93.94M ▲ | 6.98% ▲ | $1.71 ▲ | $178.59M ▲ |
| Q4-2025 | $1.32B ▼ | $187M ▲ | $75.29M ▼ | 5.71% ▼ | $1.34 ▼ | $160.07M ▼ |
| Q3-2025 | $1.35B ▼ | $170.76M ▲ | $105.98M ▲ | 7.86% ▲ | $1.87 ▲ | $198.24M ▲ |
| Q2-2025 | $1.36B ▼ | $162.86M ▲ | $96.57M ▲ | 7.09% ▲ | $1.7 ▲ | $186.37M ▲ |
| Q1-2025 | $1.4B | $153.27M | $41.2M | 2.94% | $0.69 | $117.97M |
What's going well?
Profits and earnings per share jumped, even with only modest revenue growth. The company managed to cut operating expenses significantly, showing strong cost discipline.
What's concerning?
Gross margins are slipping as costs rise faster than sales. The business remains low-margin, so any further cost increases could quickly hurt profits.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $137.59M ▼ | $4.21B ▲ | $2.49B ▲ | $1.72B ▲ |
| Q4-2025 | $260.46M ▲ | $4.07B ▼ | $2.4B ▼ | $1.67B ▼ |
| Q3-2025 | $105.38M ▼ | $4.46B ▲ | $2.69B ▲ | $1.77B ▲ |
| Q2-2025 | $155.94M ▲ | $4.2B ▲ | $2.53B ▲ | $1.67B ▲ |
| Q1-2025 | $122.87M | $4.06B | $2.41B | $1.65B |
What's financially strong about this company?
The company has positive equity, a solid current ratio, and a long history of profits. Most debt is long-term, and there are no major hidden risks.
What are the financial risks or weaknesses?
Cash reserves are falling fast, and debt is rising. Over half of assets are goodwill and intangibles, which could be written down if business weakens.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $93.94M ▲ | $-244.4M ▼ | $6.63M ▲ | $156.9M ▲ | $-80.93M ▼ | $-250.66M ▼ |
| Q4-2025 | $75.29M ▼ | $649.37M ▲ | $-3.15M ▲ | $-490.67M ▼ | $116.97M ▲ | $641.85M ▲ |
| Q3-2025 | $105.98M ▲ | $-182.72M ▼ | $-15.49M ▲ | $146.12M ▲ | $-50.56M ▼ | $-198.21M ▼ |
| Q2-2025 | $96.57M ▲ | $42.71M ▲ | $-19.37M ▲ | $8.93M ▲ | $33.07M ▲ | $25.51M ▲ |
| Q1-2025 | $41.2M | $-80M | $-22.26M | $-8.26M | $-112.89M | $-102.99M |
What's strong about this company's cash flow?
The company was able to borrow $233 million and still return $57 million to shareholders. Net income is positive, and capital spending is low.
What are the cash flow concerns?
Operating cash flow and free cash flow swung deep into the red, mainly due to working capital issues. The company is now dependent on borrowing, and cash reserves are shrinking quickly.
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Clinical Services | $500.00M ▲ | $560.00M ▲ | $570.00M ▲ | $520.00M ▼ |
Technology Solutions | $90.00M ▲ | $80.00M ▼ | $0 ▼ | $70.00M ▲ |
Revenue by Geography
| Region | Q1-2022 | Q2-2022 | Q3-2022 | Q4-2022 |
|---|---|---|---|---|
AUSTRALIA | $50.00M ▲ | $50.00M ▲ | $40.00M ▼ | $30.00M ▼ |
Rest of World | $40.00M ▲ | $50.00M ▲ | $50.00M ▲ | $40.00M ▼ |
UNITED KINGDOM | $90.00M ▲ | $110.00M ▲ | $110.00M ▲ | $110.00M ▲ |
UNITED STATES | $970.00M ▲ | $970.00M ▲ | $920.00M ▼ | $1.00Bn ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Maximus, Inc.'s financial evolution and strategic trajectory over the past five years.
Core strengths include steady revenue growth, a sharp recovery in margins and earnings, strong and recurring operating cash flow, and a solid niche position in government services. Long-standing relationships with public agencies, combined with growing technology capabilities, create meaningful barriers to entry. Liquidity has improved, giving the company more flexibility to manage working capital, invest selectively, and support shareholder returns.
Risks center on sizable and somewhat variable debt levels, volatile free cash flow and capital spending, and rising overhead costs that could pressure margins if not controlled. The business is also exposed to contract concentration, competitive bidding, and shifts in government policy or funding, which can affect both revenue visibility and pricing. The lack of a formal R&D line makes it harder to track innovation investment, raising questions about how consistently it will be funded over time.
The overall picture points to a company that has emerged from a weaker period into stronger growth and profitability, with innovation‑driven offerings that resonate with government clients. If Maximus can maintain cost discipline, manage leverage prudently, and keep advancing its technology and analytics capabilities, it appears well positioned to pursue additional contract wins and incremental margin gains. However, its future path will remain closely tied to government spending trends, competitive dynamics in federal and state contracting, and management’s choices around debt, buybacks, and investment intensity.

CEO
Bruce L. Caswell
Compensation Summary
(Year 2025)
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-07-01 | Forward | 2:1 |
| 2011-07-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 220
Ratings Snapshot
Rating : A-
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.63M
Value:$652.21M
FMR LLC
Shares:8.45M
Value:$639.06M
BLACKROCK INC.
Shares:7.59M
Value:$574.17M
Summary
Showing Top 3 of 568

